# Ryan Specialty (RYAN)

Sector: Specialty insurance brokerage

| Field | Value |
|---|---|
| Price | $47.07 |
| Market cap | $12B |
| Intrinsic value source | AI estimate |
| Data as of | 2026-11-20 |
| Next earnings | 2027-01-29 (estimate) |

Analysts: Leaning bullish

Picks: Research only

Discount category: Close to intrinsic value

## In short

The market weighs the strong record of Ryan Specialty against slower growth in a more difficult insurance market, and steady organic growth with a stable margin in 2027 can lift its value.

## Themes and gap

- Themes: High debt (leverage)
- Gap type: Slow (slow)
- Why: Organic growth and margins depend on the insurance market, and the savings of the Empower program come only by 2029.

## About

Ryan Specialty Holdings, Inc. (Ryan Specialty) is a specialty insurance firm. It works as a wholesale broker for retail insurance brokers, places risks with insurers through binding authority, and acts as a managing underwriter with authority that insurers delegate to it. It earns commissions and fees, and it does not take insurance risk itself. Total revenue was $2,501.8 million in the first nine months of 2026. Patrick G. Ryan founded the firm in 2010 and is its Executive Chairman. The public owns Class A shares, and other holders own LLC Common Units that they can exchange for Class A shares. Ryan Specialty reports in US dollars, and its Class A shares trade on the NYSE.

## Thesis

The market weighs the strong record of Ryan Specialty against slower growth in a more difficult insurance market. Organic revenue growth fell to 4.0% in Q3 2026, from 15.0% in Q3 2025, as most casualty lines grew but the property portfolio declined. Debt also rose to $3.7 billion as Ryan Specialty bought back shares and made acquisitions. The AI estimate uses a multiple of 2027 adjusted earnings per share. For the price to rise, three things must be true. Organic growth must stay in the mid-single digits or rise, as more risks move to the specialty market. The Empower program must give the savings that Ryan Specialty expects, about $80 million a year by 2029, so that the adjusted EBITDAC margin stops falling. Share buybacks and acquisitions must add to adjusted earnings per share while debt stays at a level the firm can carry. The Q4 2026 results and the 2027 outlook, expected about January 29, 2027, are the next test, and the results of 2027 show the trend. If the property business declines more or casualty growth slows, the price can stay low.

## Checkpoints

- Jan 29, 2027 (estimate): Q4 2026 results: organic growth. Status: Pending. Watch: Organic revenue growth for Q4 2026 is 4% or more and adjusted diluted earnings per share are above the $0.45 of Q4 2025, and this passes; lower growth or lower earnings per share fails.
- 2027 (estimate): 2027 margin and Empower savings. Status: Pending. Watch: The adjusted EBITDAC margin for 2027 is equal to or above the margin for 2026, and this passes; a lower margin fails.

## Valuation

The intrinsic value for Ryan Specialty is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Ryan Specialty. The method is a multiple of adjusted diluted earnings per share (EPS) for 2027, less the liability under the tax receivable agreement per share. Adjusted EPS leaves out the amortization of acquired intangible assets, changes in contingent consideration, restructuring costs and some equity-based pay, and it counts all LLC Common Units as exchanged for Class A shares. The Q3 2026 results (Form 8-K of October 29, 2026) give adjusted diluted EPS of $0.51 for Q3 2026 and $1.75 for the first nine months, on an adjusted diluted share count of 266.3 million for Q3. The Q4 2025 results of February 12, 2026 give adjusted diluted EPS of $0.45 for Q4 2025 and $1.96 for 2025. The estimate assumes 2026 adjusted EPS of about $2.22: $1.75 for the first nine months plus about $0.47 for Q4. Because EPS is after interest, the estimate makes no separate debt adjustment. The Form 10-Q gives debt principal of $3,693.1 million and cash and cash equivalents of $168.8 million at September 30, 2026. It also gives tax receivable agreement liabilities of $454.4 million, which the estimate subtracts at $1.71 per share. The cover of the Form 10-Q gives 119,694,115 Class A shares and 131,887,106 Class B shares at October 26, 2026. Each Class B share goes with an LLC Common Unit that its holder can exchange for a Class A share. The 2027 adjusted EPS and the multiples are assumptions. The low case assumes adjusted EPS of $2.20, because insurance prices fall and organic growth stays low, at 16 times. It gives $33.49 per share. The base case assumes $2.40, about 8% more than in 2026, with savings from the Empower program and share buybacks, at 20 times. It gives $46.29 per share. The high case assumes $2.60 at 24 times. It gives $60.69 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $46.69 per share. Ryan Specialty is a large wholesale broker and managing underwriter. Retail brokers and insurers depend on its specialists, its access to many insurance markets and the authority that insurers delegate to it, and these relations take years to build. These give an advantage that can last 10 years or more. But other wholesale brokers compete for the same business, and brokers can leave and take clients with them. The estimate uses no results after September 30, 2026.

As of 2026-11-14.

Sources:

- https://www.sec.gov/Archives/edgar/data/1849253/000184925326000045/ryan-20260930xex991.htm
- https://www.sec.gov/Archives/edgar/data/1849253/000184925326000047/ryan-20260930.htm
- https://www.sec.gov/Archives/edgar/data/1849253/000184925326000004/ryan-20251231xex991.htm

## Balance sheet

- Cash: $169M
- Debt: $3.7B
- Net debt: $3.5B
- EBITDA, last 12 months: $1.0B
- Net debt / EBITDA: 3.4× (medium)
- Undrawn credit line: $977M
- Debt due within 12 months: $42M
- Last debt due: 2032

At September 30, 2026, debt principal was $3,693.1 million: a term loan of $1,670.3 million, $422.8 million drawn on the revolving credit facility, $400.0 million of senior secured notes due 2030 and $1,200.0 million of senior secured notes due 2032. Cash and cash equivalents were $168.8 million, and $977.2 million of the revolving credit facility was available. Adjusted EBITDAC was $1,025.7 million in the 12 months to September 30, 2026: $222.3 million in Q4 2025 and $803.4 million in the first nine months of 2026. Fiduciary cash and receivables of $4,935.4 million belong to clients and insurers and equal the fiduciary liabilities. Tax receivable agreement liabilities were $454.4 million. In the first nine months of 2026, Ryan Specialty returned over $500 million to shareholders through dividends, distributions and share repurchases, and $150.0 million of authorization remained at September 30, 2026.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/1849253/000184925326000045/ryan-20260930xex991.htm
- https://www.sec.gov/Archives/edgar/data/1849253/000184925326000047/ryan-20260930.htm
- https://www.sec.gov/Archives/edgar/data/1849253/000184925326000004/ryan-20251231xex991.htm

## Dividends

- Dividend yield: 1.1% (last 12 months, at the current price)
- Paid per share, last 12 months: $0.52 (4 payments)
- Current annual rate: $0.52 ($0.13 x 4 a year)
- Latest ex-dividend date: 2026-11-10, $0.13 per share

Dividends per share by year: 2025: $0.48.

Some payments of 2024 are missing in the data, so no bar is shown for that year.

One-off payments far above the usual dividend are left out of these numbers.

Source: company filings and market data, read on 2026-11-13.

## Recent events

- 2026-10-29: Ryan Specialty reported Q3 2026 results. Total revenue grew 4.7% to $790.0 million, with organic growth of 4.0%. Adjusted EBITDAC grew 3.8% to $244.4 million, and adjusted diluted earnings per share grew 8.5% to $0.51. It repurchased $150.0 million of Class A shares and declared a quarterly dividend of $0.13 per share.
- 2026-07-30: Ryan Specialty reported Q2 2026 results. Total revenue grew 7.2% to $916.6 million, with organic growth of 6.7%, and adjusted diluted earnings per share grew 12.1% to $0.74. It repurchased $260.0 million of Class A shares in the quarter.
- 2026-05-26: The board increased the share repurchase authorization by $300 million, after the company used the prior $300 million authorization.
- 2026-04-30: Ryan Specialty reported Q1 2026 results, with revenue growth of 15.2% to $795.2 million and organic growth of 11.8%. It also agreed that a trust of Patrick G. Ryan will sell it shares when employees exercise new stock options, so that the options do not add shares.
- 2026-02-12: Ryan Specialty reported Q4 2025 results, with organic growth of 6.6% and adjusted diluted earnings per share of $0.45. It announced a $300 million share repurchase authorization and the Empower restructuring program, which should cost about $160 million and save about $80 million a year in 2029.

## Latest news and filings

- Last earnings: 2026-10-29 (8-K: https://www.sec.gov/Archives/edgar/data/1849253/000184925326000045/)
- Next earnings: 2027-01-29 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-10-30 | 10-Q | Quarterly report for the period ended Sep 30, 2026 | 2026-09-30 | ryan-20260930 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000047/ryan-20260930.htm |
| 2026-10-29 | 8-K | Earnings release and Other company news |  | ryan-20261029 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000045/ |
| 2026-08-07 | 8-K | New material agreement |  | ryan-20260804 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000040/ryan-20260804.htm |
| 2026-07-31 | 10-Q | Quarterly report for the period ended Jun 30, 2026 | 2026-06-30 | ryan-20260630 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000036/ryan-20260630.htm |
| 2026-07-30 | 8-K | Earnings release and Other company news |  | ryan-20260730 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000034/ |
| 2026-05-26 | 8-K | Investor disclosure |  | ryan-20260526 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000031/ryan-20260526.htm |
| 2026-05-01 | 8-K | Shareholder vote results |  | ryan-20260428 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000029/ryan-20260428.htm |
| 2026-05-01 | 10-Q | Quarterly report for the period ended Mar 31, 2026 | 2026-03-31 | ryan-20260331 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000026/ryan-20260331.htm |
| 2026-04-30 | 8-K | New material agreement |  | ryan-20260430 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000023/ryan-20260430.htm |
| 2026-04-30 | 8-K | Earnings release and Other company news |  | ryan-20260430 | https://www.sec.gov/Archives/edgar/data/1849253/000184925326000022/ |

Every filing on SEC EDGAR (CIK 1849253): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001849253&type=&dateb=&owner=include&count=40

## Risks

- High: Commissions depend on insurance prices and on the flow of risks to the specialty market. Organic growth fell to 4.0% in Q3 2026 from 15.0% a year earlier, and the property portfolio declined.
- Medium: Debt principal was $3,693.1 million at September 30, 2026, and $422.8 million was drawn on the revolving credit facility. The term loan has a floating rate.
- Medium: The tax receivable agreement liabilities were $454.4 million at September 30, 2026, and exchanges of LLC Common Units can increase them.
- Medium: Brokers and underwriters are the main asset. If key people leave for competitors, they can take clients and insurer relations with them.
- Low: Holders of LLC Common Units own about half of the firm and can exchange them for Class A shares and sell them.

## Links

- Page: https://picks.utilarium.app/company/RYAN/
- History of changes: https://picks.utilarium.app/company/RYAN/history/
- JSON with full history: https://picks.utilarium.app/data/company/RYAN.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
